Phenotypes Associated with This Genotype

Genotype
MGI:5752235

• Allelic Composition: Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh; Nras^tm1.1Nesh/Nras^tm1.1Nesh; Tg(Tyr-cre/ERT2)13Bos/0
• Genetic Background: B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

integument

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally readily develop melanoma with 70% penetrance and a median latency of 26.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

pigmentation

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

hyperpigmentation ( J:220627 )

• mice treated with 4-OHT neonatally exhibit the presence of nevi and hyperpigmented regions on the paws and tails

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally readily develop melanoma with 70% penetrance and a median latency of 26.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:220627